GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EOM Pharmaceutical Holdings Inc (OTCPK:IMUC) » Definitions » Total Current Liabilities

EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) Total Current Liabilities : $0.40 Mil (As of Jun. 2018)


View and export this data going back to 2006. Start your Free Trial

What is EOM Pharmaceutical Holdings Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. EOM Pharmaceutical Holdings's total current liabilities for the quarter that ended in Jun. 2018 was $0.40


EOM Pharmaceutical Holdings Total Current Liabilities Historical Data

The historical data trend for EOM Pharmaceutical Holdings's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EOM Pharmaceutical Holdings Total Current Liabilities Chart

EOM Pharmaceutical Holdings Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.40 1.29 2.27 3.24 2.36

EOM Pharmaceutical Holdings Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.72 7.30 2.36 1.49 0.40

EOM Pharmaceutical Holdings Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

EOM Pharmaceutical Holdings's Total Current Liabilities for the fiscal year that ended in Dec. 2017 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=2.07+0
+Other Current Liabilities+Current Deferred Liabilities
=0.291+0
=2.36

EOM Pharmaceutical Holdings's Total Current Liabilities for the quarter that ended in Jun. 2018 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.246+0
+Other Current Liabilities+Current Deferred Liabilities
=0.156+0
=0.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


EOM Pharmaceutical Holdings Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of EOM Pharmaceutical Holdings's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) Business Description

Traded in Other Exchanges
N/A
Address
136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645
EOM Pharmaceutical Holdings Inc is focused on developing novel immunomodulatory and retinal disease drug agents to address a range of inflammatory, viral, retinal, and other diseases. Its product candidate includes dual-acting broad-spectrum immunomodulator EOM613, which has the potential to treat cancer cachexia and rheumatoid arthritis, and its advanced formulation of EOM147 is being studied to treat serious retinal diseases without the need for intraocular injection.
Executives
Andrew Gengos director 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Gary Titus director, officer: Chairman and Secretary SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Mark A Schlossberg director C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Rahul Singhvi director 246 HOLLY DRIVE, CHALFONT PA 18914
Helen Susan Kim director 3832 BAY CENTER PLACE, HAYWARD CA 94545
Richard Chin director C/O OXIGENE, INC., 230 THIRD AVENUE, WALTHAM MA 02451
Richard Cowell director 7840 VIRGINIA OAK DRIVE, GAINSVILLE VA 20155
James G. Bender officer: VP, Product Development & Mfg. 112 WEST 34TH STREET, 17TH FLOOR, NEW YORK NY 10120
Manish Singh director, officer: President & CEO 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Jacqueline Brandwynne director 649 STONE CANYON ROAD, LOS ANGELES CA 90077